Sandoz Fills Pipeline Gap With Samsung Bioepis’ Ustekinumab

Strikes Deal In Multiple Global Markets For SB17 Biosimilar Rival To Stelara

 
• By Dave Wallace
  
Hand placing jigsaw puzzle piece into gap
Another piece of Sandoz’s biosimilars portfolio has fallen into place • Source: Shutterstock

More from Deals

More from Business